GlassScriptPhysician profile
Susan C Eile
NPI 1669483269
$2,208.67
in general payments reported to CMS, 2019-2025
31 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $245 · 2021: $12.79 · 2022: $133 · 2023: $199 · 2024: $217 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $330.11 | 2025 | Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $252.04 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $243.75 | 2019-2025 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $171.58 | 2023 | Ingrezza |
| Lilly USA, LLC | $166.94 | 2019-2025 | Mounjaro, Zepbound |
| Janssen Biotech, INC. | $129.64 | 2022-2024 | Stelara |
| Merck Sharp & Dohme LLC | $114.88 | 2019-2020 | |
| Amgen INC. | $106.07 | 2019 | |
| Scilex Pharmaceuticals INC. | $82.16 | 2024-2025 | |
| Mannkind Corporation | $64.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $60.82 | 2019 | |
| Baxter Healthcare | $46.86 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Glaxosmithkline, LLC. | $42.95 | 2020-2024 | Shingrix, Arexvy |
| Edwards Lifesciences Corporation | $38.10 | 2022 | |
| Pfizer INC. | $35.02 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $29.44 | 2025 | Camzyos |
| Braintree Laboratories, INC. | $26.14 | 2022 | |
| Sun Pharmaceutical Industries INC. | $24.67 | 2019 | |
| Seqirus USA INC | $24.37 | 2025 | Flucelvax, Fluad |
| Takeda Pharmaceuticals U.S.A., INC. | $22.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $21.42 | 2020 | |
| Madrigal Pharmaceuticals | $21.20 | 2024 | Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $20.99 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.15 | 2024 | Voquezna |
| Irhythm Technologies, INC. | $18.40 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $18.36 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $17.19 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.52 | 2019 | |
| Boston Scientific Corporation | $15.78 | 2019 | |
| Amarin Pharma, INC. | $14.99 | 2019 | |
| Apo-Pharma USA, INC. | $12.53 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Eile listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.